The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | How can genetic analysis be used to determine chronic lymphocytic leukemia (CLL) treatment?
Barbara Eichhorst, MD, from the University of Cologne, Cologne, Germany, discusses implications of genetic testing in chronic lymphocytic leukemia (CLL) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She describes different techniques used for genetic analysis, including FISH, Sanger sequencing and next-generation sequencing (NGS), and discusses thresholds for the proportion of CLL cells expressing particular markers and what this means for treatment. Dr Eichhorst also highlights that this examination should be done before every treatment decision.
